返回 
加入收藏
多索茶碱联合重组人干扰素α1b治疗婴幼儿中重度毛细支气管炎的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 多索茶碱联合重组人干扰素α1b治疗婴幼儿中重度毛细支气管炎的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察多索茶碱联合重组人干扰素α1b治疗婴幼儿中、重度毛细支气管炎的临床疗效及安全性。方法：将170例中、重度毛细支气管炎患儿按随机数字表法分为治疗组和对照组，各85例。两组患儿均给予常规治疗；对照组患儿在常规治疗基础上加用注射用重组人干扰素α1b 2 μg/kg加入0.9％氯化钠注射液3 mL中，压缩雾化吸入，bid；治疗组患儿在对照组基础上加用注射用多索茶碱5 mg/（kg·d）加入5％葡萄糖注射液50 mL中，ivgtt，qd。5 d为1个疗程，两组患儿均治疗1个疗程。观察两组患儿临床总有效率、治疗前后临床症状严重度评分和不良反应发生情况。结果：治疗组患儿临床总有效率为97.65％，显著高于对照组的88.24％，差异有统计学意义（P＜0.05）。治疗前，两组患儿临床症状严重度评分比较，差异无统计学意义（P＞0.05）；治疗3、5 d后，两组患儿临床症状严重度评分均显著降低，且治疗组显著低于对照组，差异均有统计学意义（P＜0.05）。仅治疗组有1例患儿出现烦燥，减慢滴速后症状消失，两组患儿均未见其他明显不良反应发生。结论：多索茶碱联合重组人干扰素α1b治疗婴幼儿中、重度毛细支气管炎疗效显著，能明显改善患儿临床症状，且安全性较好。 |
| ABSTRACT： | OBJECTIVE： To observe the clinical efficacy and safety of doxofylline combined with recombinant human interferon α1b for prediatric moderate and severe bronchiolitis. METHODS： 170 children with moderate and severe bronchiolitis were divided into treatment group and control group according to random number table， with 85 cases in each group. Both groups were given conventional treatment. Control group was additionally given compression aerosol inhalation of Recombinant human interferon α1b for injection 2 μg/kg added into 0.9％ Sodium chloride injection 3 mL， bid. Treatment group was additionally given Doxofylline for injection 5 mg/（kg·d） added into 5％ Glucose injection 50 mL， ivgtt， qd， on the basis of control group. A treatment course lasted for 5 d， and both groups received 1 course. The total effective rates of 2 groups were observed as well as clinical symptom severity score before and after treatment and the occurrence of ADR before and after treatment. RESULTS： The total effective rate of treatment group was 97.65％， which was significantly higher than 88.24％ of control group， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in clinical symptom severity score between 2 groups （P＞0.05）. After 3 d and 5 d， clinical symptom severity score of 2 groups were decreased significantly， and the treatment group was significantly lower than the control group， with statistical significance （P＜0.05）. Adverse reactions occurred in 1 patient of treatment group and disappeared after slowing down dripping speed. No other obvious ADR was fourd in 2 groups. CONCLUSIONS： Doxofylline combined with recombinant human interferon α1b show significant therapeutic efficacy for prediatric moderate and severe bronchiolitis， and can significantly improve clinical symptoms with good safety. |
| 期刊： | 2017年第28卷第2期 |
| 作者： | 付宏，李锋，曾闽榕，黄静，聂勋梅，黄昌洪 |
| AUTHORS： | FU Hong，LI Feng，ZENG Minrong，HUANG Jing，NIE Xunmei，HUANG Changhong |
| 关键字： | 多索茶碱；重组人干扰素α1b；毛细支气管炎；婴幼儿 |
| KEYWORDS： | Doxofylline； Recombinant human interferon α1b； Bronchiolitis； Prediatric |
| 阅读数： | 297 次 |
| 本月下载数： | 3 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
